Statement of Principles concerning IgA nephropathy (Balance of Probabilities) (No. 64 of 2021)

IgA nephropathy is defined in subsection 7(2) as a kidney disease characterised by two features that must both be present: deposition of immunoglobulin A in the renal mesangium demonstrated by renal biopsy, and a clinical consequence in the form of haematuria, proteinuria, or renal dysfunction. The biopsy requirement is significant because it means the diagnosis cannot rest on symptoms alone; there must be histological confirmation. The definition expressly excludes IgA vasculitis (Henoch-Schonlein purpura), which presents with IgA deposition in a systemic vasculitic context rather than a primary renal context. Subsection 7(3) cross-references ICD-10-AM codes N02.1, N02.2, N02.2.1, N02.3, N02.5, and N02.8, but makes clear that the statutory definition in subsection 7(2) governs, not the ICD coding, which matters if a coding category is broader or narrower than the statutory definition.

Death from IgA nephropathy is extended by subsection 7(5) to include death from a terminal event or condition that was contributed to by the person's IgA nephropathy. Terminal event is defined in the Schedule 1 Dictionary to include pneumonia, respiratory failure, cardiac arrest, circulatory failure, and cessation of brain function. This extension is practically important: it means that a veteran who dies of cardiac arrest contributed to by renal failure from IgA nephropathy falls within the instrument, even though the proximate cause of death is not the renal disease itself.

Relevant service is defined in Schedule 1 to cover eligible war service (other than operational service) under the VEA, defence service (other than hazardous service and British nuclear test defence service) under the VEA, and peacetime service under the MRCA. Operational service veterans face a different (lower) evidential threshold under the reasonable hypothesis SOP regime. This instrument serves the population with non-operational or peacetime service histories.

Being overweight or obese means a BMI of 25 or greater, using the standard WHO formula. One pack-year means 20 cigarettes per day for one year, or 7,300 grams of tobacco equivalent. Organic solvent is defined broadly to capture four chemical classes: aliphatic hydrocarbon solvents, aromatic hydrocarbon solvents, chlorinated organic solvents, and oxygenated organic solvents. Biologic agent is defined functionally as a therapeutic product derived from living organisms or containing components of living organisms, with examples including interferons, monoclonal antibodies, tumour necrosis factor-alpha inhibitors, tyrosine kinase inhibitors, and vascular endothelial growth factor antagonists. Chronic liver disease requires progressive destruction of liver parenchyma resulting in abnormal liver function present for at least six months. The specified list of autoimmune diseases is narrow: only coeliac disease and inflammatory bowel disease qualify.

The instrument affects three groups. First, current and former members of the Australian Defence Force who served in non-operational or peacetime capacities and who have developed IgA nephropathy or whose IgA nephropathy has worsened. This includes individuals whose service history falls under eligible war service (excluding operational service), defence service (excluding hazardous service and British nuclear test defence service), or peacetime service under the MRCA. Second, dependants of such members who have died from IgA nephropathy or a terminal event to which IgA nephropathy contributed, and who are pursuing death-related entitlements. Third, decision-makers within the Department of Veterans' Affairs, the Veterans' Review Board, and the Administrative Appeals Tribunal who must apply this instrument when assessing relevant claims.

The causal factors in section 9 suggest which service populations are most likely to engage the instrument in practice. The drug-related factors in subsections 9(4), 9(5), 9(10), and 9(11) are relevant to veterans who received particular pharmacological treatments, including biologics for cancer or autoimmune disease, during or related to their service. The organic solvent factor in subsection 9(15) is relevant to veterans who performed technical, maintenance, or industrial tasks in confined spaces, a pattern common in certain engineering and logistics trades. The liver disease and autoimmune disease factors in subsections 9(1), 9(2), 9(7), and 9(8) are relevant to veterans whose service contributed to those underlying conditions, which in turn then contributed to IgA nephropathy. The kidney transplantation factor in subsections 9(6) and 9(12) is relevant where a service-related condition led to a transplant.

The BMI and smoking factors (subsections 9(13) and 9(14)) apply only to worsening, not to onset. This reflects the medical-scientific evidence base: the RMA has concluded these exposures are supported as aggravating factors but not as sufficient to cause primary onset. Claimants with those risk factors but no other listed onset factor will be unable to establish initial service-connection under this instrument.

The instrument does not impose duties on veterans or members of the forces in the ordinary regulatory sense. Its operative effect is to create a structured entitlement pathway. Specifically, a claimant has the right to establish service-connection for IgA nephropathy or death from IgA nephropathy if, and only if, at least one factor from section 9 is shown to exist and is shown to be related to the person's relevant service (section 10(1)).

The decision-maker's obligation is to assess whether any of the 16 factors is satisfied on the balance of probabilities and whether that factor is causally linked to service. Where the disease pre-existed service but was not caused by it, the decision-maker must also determine whether the worsening factors (subsections 9(7) to 9(16)) support a finding of material contribution or aggravation under section 10(2). The instrument imposes a ceiling as well as a floor: only the listed factors can found a positive connection finding. Evidence of other potential causal factors, however medically plausible, does not satisfy the gateway under this instrument.

Section 11 creates a cascade mechanism. Where a factor in section 9 is itself an injury or disease covered by another Statement of Principles (for example, cirrhosis of the liver, coeliac disease, or inflammatory bowel disease), the factors in that other SOP apply according to their own terms as in force from time to time. This means the inquiry may extend through multiple SOPs: a claimant must trace the causal chain from service through to the intermediate condition and from the intermediate condition through to IgA nephropathy. Each link must satisfy the relevant SOP's own standard.

The drug rechallenge provisions in subsections 9(4) and 9(10) create a specific evidentiary requirement: it is not enough that a drug was taken before onset or worsening. Either the condition improved within three months of stopping or tapering the drug, or the condition redeveloped on rechallenge with the same drug. This is a pharmacological causation test that rules out temporal coincidence. The minimum seven-day exposure requirement in those subsections and in subsections 9(5) and 9(11) (biologic agents) sets a floor on the exposure duration that will be considered operative.

This instrument carries no penalties. It is not a regulatory or criminal law measure. Non-compliance by a claimant is not penalised; rather, failure to establish a factor under section 9 simply results in the claim being rejected on its merits. A decision-maker who fails to apply the instrument correctly may have their decision reviewed or overturned by the Veterans' Review Board or the Administrative Appeals Tribunal, but this is a consequence of administrative error, not a penal provision within the instrument itself.

The enforcement mechanism is structural: the instrument is binding on decision-makers under the VEA and MRCA compensation frameworks. A decision-maker cannot substitute their own medical opinion for the factors specified by the RMA. The RMA's authority under subsection 196B(3) of the VEA to determine these factors is itself the mechanism by which Parliament has constrained administrative discretion, so the instrument functions as a mandatory template rather than a guideline.

The instrument operates within the VEA and MRCA compensation framework. Its primary statutory basis is subsection 196B(3) of the VEA, which empowers the RMA to determine Statements of Principles on the balance-of-probabilities standard. It applies to claims under section 120B of the VEA (balance of probabilities claims) and section 339 of the MRCA. It does not apply to claims assessed under section 120(3) of the VEA (the reasonable hypothesis standard), which governs operational service veterans and carries a lower evidential threshold. Veterans with mixed service histories may have access to both standards depending on the nature and timing of their service.

The cascade provision in section 11 links this instrument to other SOPs. If a veteran's liver disease, coeliac disease, or inflammatory bowel disease is itself a precondition for establishing service-connection to IgA nephropathy, the relevant SOP for that intermediate condition must also be satisfied. The SOPs for those conditions must be checked in their current form, because section 11 refers to those instruments as in force from time to time, not as they stood when this SOP was made. This means amendments to intermediate SOPs can alter the effective scope of this instrument without any amendment to the instrument itself.

The instrument's definition of IgA nephropathy in subsection 7(2) governs over ICD-10-AM coding for the purpose of claims. This is relevant where a clinician has assigned an ICD code that falls within the listed range but the condition as described does not satisfy the biopsy and clinical consequence requirements in subsection 7(2), or conversely where the condition satisfies those requirements but attracts a different code.

The instrument has no direct interaction with private law, tax law, or general health regulation. Its effects are confined to the compensation and entitlements system operated under the VEA and MRCA.

The instrument repeals and replaces the Statement of Principles concerning mesangial IgA glomerulonephritis No. 53 of 2012 (Federal Register of Legislation No. F2012L01794), which was also made under subsection 196B(3) of the VEA. The renaming from "mesangial IgA glomerulonephritis" to "IgA nephropathy" reflects updated clinical terminology. No further amendment history prior to this instrument is recorded in the source document. The source does not identify intermediate amendments to the 2012 SOP before its repeal, and no additional historical versions are described. Changes in the factor list between the 2012 instrument and the current one cannot be identified from the source alone, as the repealed instrument's content is not reproduced in the source document.

The current instrument commenced on 21 June 2021, one month after being signed on 21 May 2021. This gap is standard for RMA instruments and allows time for publication and administrative preparation.

The source document names no cases. No litigation arising from this instrument or its predecessor is identified in the text. The instrument does not reference any tribunal decisions or court judgments that informed the factors selected by the RMA. Accordingly, no litigation history can be stated from the source.

It is common for VEA Statement of Principles to be engaged in proceedings before the Veterans' Review Board and the Administrative Appeals Tribunal, where the interpretation of specific factor requirements (for example, the drug rechallenge test or the minimum exposure duration for organic solvents) is contested. However, any such cases exist outside the source document and cannot be reported here without inventing material not grounded in the source.

Several features of the instrument are likely to cause difficulty in practice.

First, the biopsy requirement in the definition of IgA nephropathy (subsection 7(2)) is absolute. A claimant who has haematuria and a clinical presentation consistent with IgA nephropathy but has not undergone renal biopsy cannot establish the condition for purposes of this instrument. Veterans who were managed conservatively without biopsy, or whose biopsy records are lost, face a threshold evidentiary problem that is not addressed by the instrument itself.

Second, the exclusion of IgA vasculitis (Henoch-Schonlein purpura) in subsection 7(2)(b) means that veterans with a diagnosis on the vasculitic spectrum must demonstrate that their condition is primary renal rather than systemic. Where the clinical picture is ambiguous, this exclusion may be contested.

Third, the specified list of autoimmune diseases in Schedule 1 is narrow: only coeliac disease and inflammatory bowel disease are included. Many autoimmune conditions that can co-present with IgA nephropathy in the medical literature (for example, ankylosing spondylitis or lupus) are not on the list. A veteran with a different autoimmune condition cannot use subsection 9(2) or 9(8) regardless of clinical plausibility.

Fourth, the worsening factors include BMI of 25 or greater (subsection 9(13)) and a smoking history of at least 5 pack-years in the preceding 10 years (subsection 9(14)), but these apply only to worsening, not to onset. A veteran who smoked heavily during service and subsequently developed IgA nephropathy cannot rely on smoking as an onset factor; it is relevant only if the disease was already present and service-related before worsening.

Fifth, the drug rechallenge or improvement requirement in subsections 9(4) and 9(10) imposes a pharmacological causation standard that is difficult to satisfy retrospectively. A treating clinician is unlikely to have conducted a formal rechallenge, and the three-month improvement window after discontinuation requires contemporaneous clinical records to verify.

Sixth, the organic solvent exposure factor in subsection 9(15) applies only to worsening and requires both a frequency threshold (average of at least two hours per week) and a duration threshold (at least one year within the five years before clinical worsening) in an unventilated and confined space. All three conditions (frequency, duration, and environment type) must be met concurrently. Records of occupational exposure to this specificity are often unavailable for historical service periods.

Seventh, the cascade in section 11 means that a claimant relying on an intermediate condition such as cirrhosis or inflammatory bowel disease must satisfy the SOP for that condition as well. Each link in the chain must be independently established. If the intermediate SOP is amended adversely after the IgA nephropathy claim is lodged but before it is decided, the current version of the intermediate SOP governs (because section 11 refers to instruments as in force from time to time), which could affect outcome.

Eighth, subsection 9(16), which covers inability to obtain appropriate clinical management for IgA nephropathy, applies to worsening only. It is broadly worded but offers no guidance on what constitutes "appropriate clinical management" or what circumstances constitute "inability" to obtain it. This factor invites dispute about what the standard of care requires and whether particular service conditions rendered it inaccessible.

This instrument does not impose regulatory compliance obligations on veterans or service members. The practical question for claimants and their representatives is how to assemble a claim that satisfies the instrument's requirements.

A claimant should begin by confirming the diagnosis. The definition in subsection 7(2) requires a renal biopsy showing IgA deposition in the mesangium and a clinical consequence (haematuria, proteinuria, or renal dysfunction). A treating specialist's report should confirm these elements explicitly rather than relying solely on an ICD code.

The claimant should then review each factor in section 9 and identify which, if any, is capable of being established on the balance of probabilities. For onset claims (subsections 9(1) to 9(6)), the relevant question is which condition or exposure predated clinical onset and can be linked to service. For aggravation claims (subsections 9(7) to 9(16)), the relevant question is which condition or exposure predated clinical worsening and can be linked to service, given that the disease itself pre-existed or arose during (but not from) service.

Where the claim depends on an intermediate condition covered by another SOP (section 11), the claimant must separately establish service-connection for that intermediate condition under the applicable SOP. Specialist medical evidence addressing each causal link in the chain is necessary.

For drug-related claims under subsections 9(4) or 9(10), the claimant needs contemporaneous records showing the drug was taken for at least seven days before onset or worsening, plus either documented improvement within three months of cessation or documented worsening on rechallenge. Clinical notes from the treating period are essential.

For organic solvent exposure under subsection 9(15), the claimant should obtain employment or service records showing the nature of the work, the frequency of exposure, and the physical environment. A statement from a medical or occupational hygiene expert connecting the exposure pattern to the statutory requirements is likely to be necessary.

For BMI or smoking claims under subsections 9(13) and 9(14), the claimant must establish that the BMI of 25 or greater persisted for at least five years before clinical worsening, or that at least five pack-years were accumulated in the ten years before worsening, and that those states were related to service (for example, dietary conditions during service contributing to sustained overweight). The service-connection requirement in section 10(1) applies to all factors, so the lifestyle factor alone is not sufficient; it must be traceable to service circumstances.

Finally, a claimant relying on subsection 9(16) (inability to obtain appropriate clinical management) should document the specific circumstances that prevented access to care and explain how those circumstances arose from service. Vague assertions about difficulty accessing medical care during service are unlikely to satisfy the balance-of-probabilities standard without contemporaneous records or specific evidence.